Drospirenone in the treatment of severe premenstrual cerebral edema in a woman with antiphospholipid syndrome, lateral sinus thrombosis, situs inversus and epileptic seizures

Gynecological Endocrinology

Volumn 21, Issue 5, 2005, Pages 243-247

  Vujović, Svetlana ^a   Zidverc, Jasna ^a   Stojanović, Miloš ^a   Penezić, Zorana ^a   Ivović, Miomira ^a   Dukić, Vladimir ^a   Drezgić, Milka ^a  

^a CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

Cerebral edema; Epileptic seizures; Estradiol; Premenstrual syndrome; Progesterone

Indexed keywords

ANTICOAGULANT AGENT; BENZODIAZEPINE; BIGUANIDE; DIURETIC AGENT; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTRADIOL; ETHINYLESTRADIOL; FLUOXETINE; INSULIN; MINERALOCORTICOID ANTAGONIST; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; PROLACTIN; SPIRONOLACTONE;

ADULT; ANAMNESIS; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLURRED VISION; BRAIN EDEMA; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; DEPRESSION; DIAGNOSTIC TEST; FEEDING BEHAVIOR; FEMALE; HEADACHE; HORMONE DETERMINATION; HUMAN; IRRITABILITY; LATERAL SINUS THROMBOSIS; LUTEAL PHASE; MENSTRUAL CYCLE; MENSTRUATION; PAPILLEDEMA; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; SEIZURE; SITUS INVERSUS; SYMPTOM; THROMBOPHILIA; URINE INCONTINENCE;

EID: 29944433431     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590500361853     Document Type: Article

References (33)

1. Panay N, Studd J. Progesterone intolerance in the treatment of severe premenstrual syndrome. In: The 11th World Congress of Gynecological Endocrinology, 2004, Florence. London: The Parthenon Publishing Group; 2004. p 177.
2. Hammarback S, Ekholm UB, Backstrom T. Spontaneous anovulation causing appearance of cyclical symptoms in women with PMS. Acta Endocrinol 1991;125:132-137.
3. Studd JWW. Premenstrual syndrome. Br Med J 1979;1:410-415.
4. Backstrom T, Boyle H, Baird DT. Persistence of symptoms of premenstrual tension in hysterectomized women. Br J Obstet Gynaecol 1981;88:530-536.
5. Vujovic S. No evidence of premenstrual syndrome in female-to-male transsexuals. Gender Dysphoria 1992;2:56-68.
6. Poort SR, Rosental FR, Reitsma PH, Bertina RN. A common genetic variation in the 3-transected region of prothrombin gene is associated with elevated plasma prothrombin level and increase in venous thrombosis. Blood 1996;88:3698-3703.
7. Soria JM, Almasy L, Souto JC, Tirado I, Borell M, Mateo J, Slifer S, Stone W, Blangero J, Fountcuberta J. Linkage analysis demonstrates that the prothrombin G20210A mutation jointly influences plasma prothrombin levels and risk of thrombosis. Blood 2000;95:2780-2785.
8. Carhuapoma JR, Mitsias P, Levine SR. Cerebral venous thrombosis and anticardiolipin antibodies. Stroke 1997;28: 2363-2369.
9. Moos RH. The development of a menstrual distress questionnaire. Psychosom Med 1968;30:853-867.
10. Mortola JF, Girton L, Beck L, Yen SS. Diagnosis of premenstrual syndrome by a simple, prospective and reliable instrument: the calendar of premenstrual experience. Obstet Gynecol 1990;76:302-307.
11. Leker RR, Steiner I. Anticardiolipin antibodies are frequently present in patients with idiopathic intracranial hypertension. Arch Neurol 1998;55:817-820.
12. Vujovic S. Ultrasongrafske i funkcionale karakteristike ovarijuma u žena sa predmenstrucionim sindromom [dissertation], Beograd: University of Beograd; 1991.
13. Redei E, Freeman EW. Daily plasma estradiol and progesterone levels over the menstrual cycle and their relation to premenstrual symptoms. Psychoneuroendocinology 1995;20: 259-267.
14. Hammaback S, Damber JE, Backstrom T. Relationship between symptom severity and hormone changes in women with premenstrual syndrome. J Clin Endocrinol Metab 1989; 68:125-130.
15. Backstrom T, Sanders D, Leask R, Davidson D, Warner P, Bancroft J. Mood, sexuality, hormones and the menstrual cycle. II. Hormone levels and their relationship to the premenstrual syndrome. Psychosom Med 1983;45:503-507.
16. Smith MJ, Schmidt PJ, Su T-P, Rubinow DR. Gonadotropin releasing hormone-stimulated gonadotropin levels in women with premenstrual dysphoria. Gynecol Endocrinol 2004;19: 335-343.
17. Petitclerc M, Bedard PJ, Di Paolo T. Progesterone releases dopamine in male and female rat striatum. A behavioural and microdialysis study. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:491-497.
18. Sinchak K, Micevych PE. Progesterone blockade of estrogen activation of μ-opioid receptors regulates reproductive behaviour. J Neurosci 2001;21:5723-5729.
19. Limmroth U, Lee WS, Moskowitz MA. GABA-A receptor-mediated effects of progesterone, its ring-A-reduced metabolites and synthetic neuroactive steroids on neurogenic oedema in the rat meninges. Br J Pharmacol 1996;117:99-104.
20. Genazzani AR, Stomati M, Morittu A, Bernardi F, Monteleone P, Casarosa E, Gallo R, Salvestroni C, Luisi M. Progesterone, progestogens and the central nervous system. Hum Reprod 2000;15(Suppl): 14-27.
21. Walker RF, Wilson CA. Changes in hypothalamic serotonin associated with amplification of LH-surges by progesterone in rats. Neuroendocrinology 1983;37:200-205.
22. Brzezinski AA, Wurtman JJ, Wurtman RJ, Gleason R, Greenfield J, Nader T. D-Fenfluramine suppresses the increased calorie and carbohydrate intakes and improves the mood of women with premenstrual depression. Obstet Gynecol 1990;76:296-301.
23. Pearlstein TB, Stone AB. Long-term fluoxetine treatment of late luteal phase dysphoric disorder. J Clin Psychiatry 1994;55:332-335.
24. Corney RH, Stanton R. A survey of 658 women who report symptoms of premenstrual syndrome. J Psychosom Res 1991; 35:471-482.
25. Oelkers W, Helmerhorst FM, Wuttke W. Effects of an oral contraceptive containing drospirenone on the rennin-angiotensin-aldosterone system in healthy female volunteers. Gynecol Endocrinol 2000;16:204-213.
26. Freeman EW, Kroll R, Rapkin A, Pearlstein T, Brown C, Parsey K, Zhang P, Patel H, Foegh M; PMS/PMDD Research Group. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med 2001;10:561-569.
27. Apter D, Borsos A, Baumgartner W, Melis GB, Vexiau-Robert D, Colligs-Hakert A, Palmer M, Kelly S. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general wellbeing and fluid-related symptoms. Eur J Contracept Reprod Health Care 2003;8:37-51.
28. Baltatu O, Bade M. Brain rennin-angiotensin system. Neuroendocrinology 2003;78:253-259.
29. Nanaka E, Emoto N, Iheda K, Fukuya H, Rohman MS, Raharjo SB, Yagita K, Okamura H, Yokoyama M. Angiotensin II induces circadian gene expression of clock genes in culture of vascular smooth muscle cells. Circulation 2001;104:1746-1748.
30. Yamakawa H, Phillips MI, Saavedra JM. Intracisternal administration of angiotensin II AT (1) receptor antisense oligodeoxynucleotides protects against cerebal ischemia in spontaneously hypertensive rats. Regul Pept 2003;111:117-122.
31. Eriksson KT, Simblad C, Lispo P, Modigh K, Andersch B. Serum levels of androgen are higher in women with premenstrual irritability and dysphoria than in controls. Psychoneuroendocrinology 1992;17:195-204.
32. Muhn P, Fuhrmann U, Fritzemeier KH, Krattenmacher R, Schillinger E. Drospirenone: a novel progestogen with antimineralocirticoid and antiandrogen activity. Ann N Y Acad Sci 1995;761:311-335.
33. Vandenbroucke JP, Rosing J, Bloemenkamp KW, Middeldorp S, Helmerhorst FM, Bouma BN, Rosendaal FR. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001;344:1527-1535.